1st Quarter - Report — JOHNS HOPKINS UNIVERSITY for JOHNS HOPKINS UNIVERSITY (2015)

Firm

JOHNS HOPKINS UNIVERSITY

Client

JOHNS HOPKINS UNIVERSITY

Income

—

Expenses

$120,000

Expense method

A: Lobbying Disclosure Act definitions

What was lobbied

9 issue areas, each in the filer's own words, with who lobbied on it and where.

Defense DEF

Uniformed Services Family Health Plan

Lobbyist	Covered position, as disclosed
MELISA LINDAMOOD	—

Contacted: SENATE; Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES

Taxation/Internal Revenue Code TAX

New Markets Tax Credit

Lobbyist	Covered position, as disclosed
JEFFREY GROSSI	—

Contacted: HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); SENATE

Health Issues HCR

Health care quality and safety; Ophthalmology injected device policy; nursing policy issues; alternatives to animal toxicity testing

Lobbyist	Covered position, as disclosed
BETH ANN FELDER	—
MELISA LINDAMOOD	—
DAVID PARKER	—

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA)

Foreign Relations FOR

US-China higher education relations

Lobbyist	Covered position, as disclosed
JEFFREY GROSSI	—

Contacted: HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); SENATE; Centers For Medicare and Medicaid Services (CMS)

Graduate medical education funding; Recovery audit contractors; Medicare physician payment - sustainable growth rate formula, H.R. 2 Medicare Acccess and CHIP Re-authorization; Children's Health Insurance Program; Medicare/Medicaid coverage issues, H.R. 605 Home Infusion Site of Care Act; Durable medical equipment competitive bidding, H.R. 2021 Protecting the Integrity of Medicare Act; Hospital readmissions policy, S.688/H.R. 1343 Establishing Beneficiary Equity in the Hospital Readmission Program Act; Reimbursement policy of pharmacy services, H.R. 592 Pharmacy and Medically Underserved Areas Enchancement Act; Innovation Grants

Lobbyist	Covered position, as disclosed
BETH ANN FELDER	—
MELISA LINDAMOOD	—
DAVID PARKER	—

Contacted: SENATE; Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA)

Bills named: S. 688 (114th), H.R. 2021 (114th), H.R. 592 (114th), H.R. 605 (114th), H.R. 2 (114th), H.R. 1343 (114th)

Education EDU

Nurse training and student loans/scholarships

Lobbyist	Covered position, as disclosed
DAVID PARKER	—

Contacted: HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); SENATE; Centers For Medicare and Medicaid Services (CMS)

Science/Technology SCI

Biomedical research and innovation; Intellectual property and patent policy; EPA research regulations and requirements, H.R. 1030 Secret Science Reform Act

Lobbyist	Covered position, as disclosed
BETH ANN FELDER	—
JEFFREY GROSSI	—
MELISA LINDAMOOD	—

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS)

Bills named: H.R. 1030 (114th)

Budget/Appropriations BUD

Funding for National Institutes of Health; Ebola preparedness funding; FY16 appropriations

Lobbyist	Covered position, as disclosed
BETH ANN FELDER	—
JEFFREY GROSSI	—
MELISA LINDAMOOD	—

Contacted: Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); SENATE; HOUSE OF REPRESENTATIVES

Pharmacy PHA

Pharmaceutical drug price increases; 340B drug discount program

Lobbyist	Covered position, as disclosed
MELISA LINDAMOOD	—

Contacted: Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; SENATE; Centers For Medicare and Medicaid Services (CMS)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.